- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03158974
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of External Genital Warts
A Phase 2, Open-label, Safety, Tolerability, and Efficacy Trial of a Botanical Drug at One Dose Level for the Treatment of External Condylomata Acuminata (Genital Warts) in Adult Immunocompetent Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This trial will be a phase 2, open-label, study to evaluate the safety, tolerability, and efficacy of VIR007 when administered topically for up to 60 days to adults between the ages of 18 to 65 years with a clinical diagnosis of external condylomata acuminata.
Subjects will enter the Screening Period once the informed consent process has been completed. Subjects with a clinical diagnosis of external condylomata acuminata and who meet all inclusion and none of the exclusion criteria will be enrolled.
Once subject eligibility is confirmed and the screening procedures completed, the subject will start the Treatment Period of the study. All enrolled subjects will receive VIR007 (cream containing 10% EISO) with the first dose applied topically during Visit 1 (Day 1). Subjects will be instructed on how to apply the study medication twice daily for up to 60 days or until the Investigator determines the lesions have cleared. Subjects will return to the clinic for study-related assessments on Study Days 7, 14, 28, 42 and a Final Study Visit on Day 60. 30 days following complete resolution, as determined by the study investigator, or, on Study Day 90, subjects will receive a follow-up telephone call and be queried regarding condition status since study completion.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78231
- Progressive Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Are ≥18 but ≤65 years of age
- Are in good general health, as confirmed by medical history
- Have a clinical diagnosis of condylomata acuminata with ≥2 but ≤10 visible external genital warts (EGWs)
- Have EGW lesions <200mm2
- Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events.
- Must be willing to use a barrier method of birth control while enrolled in the study.
- If female of childbearing potential, must have a negative urine pregnancy test result prior to study treatment and must be willing to use a barrier method of birth control while enrolled in the study.
- Are willing to refrain from using any lotions, moisturizer, cleansers, cosmetics or creams, other than those issued as part of the study, on the affected areas during the treatment period.
- Are able to give written informed consent in a manner approved by the Institutional Review Board or Ethics Review Committee and comply with the requirements of the study.
- Are willing to avoid participation in any other clinical trial for the duration of this study.
- Are willing and able to participate as an outpatient, making regularly scheduled visits to the study center during the treatment and to comply with all study requirements including concomitant medication and other treatment restrictions.
- Are willing to forgo all other treatments (prescription, nonprescription, and nutritional supplements) for their EGWs.
Exclusion Criteria:
- Have evidence of an active malignancy or have been immunocompromised within the 60 days prior to Screening.
- Received any treatment for their EGW within 60 days of planned study enrollment.
- Are pregnant, breast-feeding, or planning to become pregnant during the study.
- Have EGWs ≥200mm2.
- Have any evidence, currently or in the last 60 days, of herpes genitalis or any other current and/or recurrent genital or uncontrolled infection that, in the opinion of the investigator, could confound the results of the study including human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C.
- Have any abnormal skin conditions, body piercings, hypertrophic scarring or body modification in the area that, in the opinion of the investigator, might affect the accurate evaluation of EGWs.
- Shares a household with a subject currently enrolled in the study.
- Have any condition that, in the opinion of the investigator, would confound the safety and/or efficacy assessments.
- Have internal genital wart lesions, including the urethra, vagina and/or rectum.
- If female, have any evidence of cervical dysplasia.
- Have evidence of clinically significant or unstable disease (eg, stroke, heart attack).
- Have a known sensitivity to any of the constituents of the test product including sensitivities to sandalwood oil, fragrances or any member of the Compositae family of vascular plants (eg, sunflowers, daisies, dahlias, etc.).
- Have a history of Bowenoid papulosis.
Have received any of the following within 90 days prior to study treatment:
- Interferon or interferon inducers
- Cytotoxic drugs
- Immunomodulators or immunosuppressive therapies (inhaled/intranasal corticosteroids are permitted)
- Oral or parenteral corticosteroids
- Topical corticosteroids if greater than 2 gm/day
- Any dermatologic procedures or surgeries on the study area (including EGW treatments)
- Have a history of alcohol abuse, or suspected alcohol abuse, in the past two years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: VIR007
Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
|
Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent adverse events
Time Frame: 60-days
|
Safety will be assessed by evaluating adverse events (AEs) with respect to severity, duration, and relationship to study drug.
|
60-days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent tolerability issues
Time Frame: 60-Days
|
Tolerability will be assessed by the number of subjects reporting discomfort either during or immediately following the application of VIR007
|
60-Days
|
Percentage of patients achieving complete clearance
Time Frame: 60-days
|
The percentage of subjects achieving complete clearance of all EGW lesions over the course of the trial
|
60-days
|
Time to clearance
Time Frame: 60-days
|
Time to clearance over the trial
|
60-days
|
Remission
Time Frame: 90-days
|
Percentage of subjects continuing in remission at the follow-up call
|
90-days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mark Lee, MD, Progressive Clinical Trials
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VIR007-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Condylomata Acuminata
-
Jun ZhangXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...Completed
-
Jun ZhangXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...Active, not recruiting
-
Maruho Co., Ltd.Leiden University Medical CenterCompletedCondylomata Acuminata (External)Netherlands
-
Zydolab - Institute of Cytology and Immune CytochemistryRuhr University of BochumRecruitingCondylomata AcuminataGermany
-
VaxartCompletedCondylomaArgentina, Chile, Ecuador, Serbia
-
Shenzhen Second People's HospitalUnknown
-
G&E Herbal Biotechnology Co., LTDCompletedGenital Warts | Condylomata Acuminata | Condyloma Acuminata | Venereal WartsTaiwan
-
Integra LifeSciences CorporationActive, not recruitingCondylomata Acuminata | Vulvar Intraepithelial NeoplasiaUnited States
-
BioMAS LtdCompletedCondyloma Acuminata | Wart; External Genital OrgansIsrael
-
Laboratorio Elea Phoenix S.A.TerminatedRecurrent Condyloma | Nonrecurrent CondylomaArgentina
Clinical Trials on East Indian Sandalwood Oil Cream
-
Santalis Pharmaceuticals, Inc.Derm Research, PLLC; ClinDatrix, Inc.; Texas Dermatology and Laser Specialists; Clinical Trials of Texas, Inc... and other collaboratorsCompletedEczema | Atopic DermatitisUnited States
-
ViroXis CorporationTerminatedMolluscum ContagiosumUnited States
-
ViroXis CorporationCompletedCommon WartsUnited States
-
Santalis Pharmaceuticals, Inc.The University of Texas Health Science Center at San AntonioCompletedOral MucositisUnited States
-
Petra LarmoCliniscan LtdTerminated
-
Aisha Mohammed Hamziclinical professorNot yet recruiting
-
Institute of Skin and Product Evaluation, ItalyAromtech Ltd.Unknown
-
University of LouisvilleCompletedMenopause | Atrophic Vaginitis | Recurrent Urinary Tract InfectionsUnited States
-
Uppsala UniversityLund University; Arla Foods; Vinnova; The Swedish Research Council for Environment... and other collaboratorsCompletedHypercholesterolemiaSweden
-
USDA Grand Forks Human Nutrition Research CenterTerminated